BRCA1 and ovarian carcinoma: Reduced expression or activity of BRCA1 due to mutations or epigenetic silencing might result in the reactivation of the aromatase gene, which might lead to abnormal estrogen synthesis and thereby promote breast and ovarian cancer development.